Surgical management of the lateral neck compartment for metastatic thyroid cancer.
OBJECTIVE
The lateral neck compartment is the second most frequent target region for metastatic papillary thyroid cancer (PTC) and medullary thyroid cancer (MTC). Lateral lymph node metastases are associated with locoregional recurrence and, when they involve either side of the neck, with mediastinal and distant metastases.


RESULTS
For tumors originating from the upper thyroid pole, the first nodal basin is not invariably the central compartment (as for primaries arising from the inferior thyroid pole) but often the upper part of the ipsilateral lateral compartment. Lymph node dissection of the first basin may differ depending on the location of the primary tumor. Involvement of the contralateral lateral compartment is seen in PTC with extensive central compartment involvement, and in MTC with preoperative basal calcitonin levels more than 200  pg/ml (normal limit <10  pg/ml).


CONCLUSIONS
After lateral lymph node dissection for metastatic thyroid cancer, dysfunction of lateral neck nerves is fairly common. This observation underpins the importance of striking a balance between oncological benefit and surgical risk. Lateral lymph node dissection may be warranted for an upper thyroid pole primary, for a tumor with extensive involvement of the central compartment, and for an MTC with increased basal calcitonin level of 20-200  pg/ml (ipsilateral dissection) or more than 200  pg/ml (bilateral dissection).
Department of Surgery, University Hospital, University of Halle-Wittenberg, Halle, Germany. henning.dralle@uk-halle.de
Henning
H
Dralle
Andreas
A
Machens
D018276:Carcinoma, Medullary / Q000556:secondary / Q000601:surgery*; D002291:Carcinoma, Papillary / Q000556:secondary / Q000601:surgery*; D006801:Humans; D008197:Lymph Node Excision / Q000009:adverse effects / Q000379:methods; D037981:Neck Dissection / Q000009:adverse effects / Q000379:methods*; D013964:Thyroid Neoplasms / Q000473:pathology / Q000601:surgery*; D013965:Thyroidectomy / Q000009:adverse effects / Q000379:methods*